A hub built on high value, not high volume
Singapore does not make the most medicine in Asia. It makes some of the most valuable, most tightly regulated and most technically demanding. The island hosts more than 60 biopharmaceutical manufacturing plants, including facilities for eight of the world’s ten largest drugmakers, on a landmass smaller than most of the metropolitan regions its customers ship to. Biomedical manufacturing was the third-strongest cluster of 2025, adding 16.3% in value-added over the year — a pace that says less about a single good year than about a base global producers keep deepening.
The economics are unusual, and they matter for anyone reading the numbers. Biopharmaceutical output was S$12.1bn in 2024, down from more than S$18bn in 2023. That fall is not decline; it is the signature of the business. A handful of large plants making a small number of high-value active ingredients and biologics means output tracks product cycles and campaign schedules rather than any smooth national trend. Read Singapore’s pharma numbers by the year, not by the line through them.
Why the majors are here
The pull is a stack of advantages that individually exist elsewhere and collectively exist almost nowhere. Singapore’s Health Sciences Authority (HSA) is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), which means Good Manufacturing Practice (GMP) certification carries weight across the scheme’s participating authorities. GMP is not a badge here; it is the licence to manufacture, and the reason a plant in Tuas can ship regulated product into the United States, the European Union and Japan without relitigating its quality system in each market.
Around that regulatory spine sits the rest: political stability, enforced intellectual-property protection, a deep-water port, and a skilled biopharmaceutical workforce that has grown substantially over the past decade. Public institutions have invested heavily in biomedical-sciences R&D, and industry output has roughly doubled over two decades. None of this is cheap, and Singapore does not compete on cost — it competes on the certainty that a batch made here will pass inspection anywhere.
The pharma majors and their plants
The roll-call reads like the industry’s top table. AstraZeneca is building a US$1.5bn facility — its first end-to-end antibody-drug-conjugate (ADC) site anywhere — targeting operations around 2029 and more than 800 hires, designed to run at net-zero carbon. It is the single largest recent commitment and a statement about where the company sees complex oncology manufacturing heading. Pfizer has committed a further US$743m to expand its long-standing Tuas operations; Sanofi has built a roughly US$590m modular vaccine and biologics plant; Novartis (US$256m) and AbbVie (US$223m) round out a cluster of nine-figure expansions.
Alongside them sit MSD, Amgen, Roche, Takeda and others, plus the contract heavyweights among the CDMOs. The mix is deliberate. Innovator plants making patented small molecules and active pharmaceutical ingredients sit near biologics facilities and near the contract manufacturers that give smaller drug developers a route into the same regulatory environment. A company need not own a plant in Singapore to make its product to Singapore’s standard.
Biologics, small molecules and cell-and-gene
The three broad manufacturing modes make very different demands, and Singapore hosts all three. Small-molecule active-ingredient production — classical chemical synthesis — is the island’s oldest biomedical strength, concentrated where feedstock, utilities and containment already exist. Biologics is the growth story: large-molecule drugs grown in living cells demand bioreactor suites, single-use systems and cold-chain rigour that dwarf a chemical plant’s, and it is here that AstraZeneca’s ADC site and Sanofi’s modular plant place their bets. Cell-and-gene therapy is the frontier — smaller batch sizes, patient-specific in some cases, and a regulatory path still maturing — and Singapore has positioned for it through public research capacity and the same GMP backbone. The through-line is that Singapore captures the steps where getting it wrong is catastrophic and getting it right is worth a great deal.
MedTech: the quieter, steadier half
If pharma is the volatile earner, medical technology is the steadier one. MedTech output reached S$19.4bn in 2023 — nearly four times its 2013 level, one of the more striking growth curves in Singapore manufacturing. The sector employs around 17,000 people across 400-plus enterprises, and leans on a supplier base of thousands of precision-engineering and electronics-manufacturing firms. The products are high-value and often implantable: cardiac devices, life-sciences instruments, lenses, diagnostics. Because devices carry longer product cycles and less campaign-driven lumpiness than biologics, MedTech gives the biomedical cluster a ballast that pharma alone would not.
Why output swings — and why that is not a warning
The single most misread fact about Singapore’s biomedical numbers is their volatility. The drop in pharma output between 2023 and 2024 would, in most sectors, signal trouble. Here it signals product mix. When a plant runs a large campaign of a high-value active ingredient, national output jumps; when that campaign ends or shifts to another molecule, output falls, even as the plant, the jobs and the investment stay exactly where they were. The durable signals are investment commitments, headcount and value-added — and all three point up, with biomedical the third-strongest cluster of 2025 at +16.3%.
Regulation, talent and the two campuses
Two locations anchor the physical hub. Tuas Biomedical Park is the manufacturing campus — purpose-built plots with shared utilities and room to scale, home to most of the majors’ plants. Biopolis, the research campus, houses the public and private R&D that feeds the pipeline. The division of labour is clean: discovery and translational science at Biopolis, GMP production at Tuas. Regulation is the binding constraint and the competitive moat: HSA’s PIC/S membership, GMP for drug product, and ISO 13485 for medical-device quality management are the licences that let Singapore-made product move into the world’s most demanding markets. Talent is the other constraint — every large expansion is, in effect, a hiring commitment.
The supplier base that makes it possible
Behind every plant sits an ecosystem that rarely makes headlines but decides whether a facility runs. GMP and ISO 13485 manufacturing depend on contract development and manufacturing organisations (CDMOs), precision-machined components, single-use and sterile packaging, cleanroom construction and certification, and calibration and validation services that keep instruments and processes inside their qualified limits. A validation failure can halt a batch worth millions; a cleanroom that drifts out of specification can idle a suite. The precision and electronics suppliers feeding MedTech, and the specialist sterile-packaging and validation firms feeding pharma, are the reason a plant here can promise consistency — and consistency is the whole product.
Outlook
The direction is set. AstraZeneca’s ADC plant, Pfizer’s expansion and Sanofi’s modular facility are multi-year builds that will lift capacity and headcount well past 2029, and the pipeline of biologics and complex oncology drugs plays to exactly the high-containment, high-value work Singapore does best. Expect pharma output to keep swinging by year while investment, jobs and value-added trend up; expect MedTech to keep compounding off its S$19.4bn base. The risks are real — cost, land and talent scarcity, and competition from other Asian hubs — but the moat is regulatory and reputational, and it does not erode quickly. For an industrial buyer, the practical read is simple: if a product must be made to a standard that survives inspection anywhere, Singapore remains one of the few places on earth that can prove it.